2033例非输血依赖型β地中海贫血患者的生存情况及死因 - Suppr

Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia.

作者信息

Musallam Khaled M, Vitrano Angela, Meloni Antonella, Pollina Sebastiano Addario, Karimi Mehran, El-Beshlawy Amal, Hajipour Mahmoud, Di Marco Vito, Ansari Saqib Hussain, Filosa Aldo, Ricchi Paolo, Ceci Adriana, Daar Shahina, Vlachaki Efthymia, Singer Sylvia Titi, Naserullah Zaki A, Pepe Alessia, Scondotto Salvatore, Dardanoni Gabriella, Bonifazi Fedele, Sankaran Vijay G, Vichinsky Elliott, Taher Ali T, Maggio Aurelio

机构信息

Thalassemia Center, Burjeel Medical City, Abu Dhabi, UAE

Campus of Haematology Franco and Piera Cutino, AOOR Villa Sofia-V. Cervello, Palermo.

出版信息

Haematologica. 2021 Sep 1;106(9):2489-2492. doi: 10.3324/haematol.2021.278684.

DOI:10.3324/haematol.2021.278684

PMID:33882642

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8409024/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d32f/8409024/339ff7f645ea/1062489.fig1.jpg

相似文献

Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia.

Haematologica. 2021 Sep 1;106(9):2489-2492. doi: 10.3324/haematol.2021.278684.

Morbidities and mortality in transfusion-dependent Beta-thalassemia patients (single-center experience).

Pediatr Hematol Oncol. 2013 Mar;30(2):93-103. doi: 10.3109/08880018.2012.752054. Epub 2013 Jan 9.

Red cell alloimmunization in transfusion-dependent and transfusion-independent beta thalassemia: A review from the Eastern Mediterranean Region (EMRO).

Transfus Apher Sci. 2019 Dec;58(6):102678. doi: 10.1016/j.transci.2019.102678. Epub 2019 Nov 7.

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.

Haematologica. 2019 Mar;104(3):477-484. doi: 10.3324/haematol.2018.198887. Epub 2018 Oct 18.

Disease severity scoring system for non-transfusion-dependent thalassemia.

Eur J Intern Med. 2016 May;30:e11. doi: 10.1016/j.ejim.2015.12.008. Epub 2016 Jan 4.

Molecular basis of transfusion dependent beta-thalassemia major patients in Sabah.

J Hum Genet. 2014 Mar;59(3):119-23. doi: 10.1038/jhg.2013.131. Epub 2013 Dec 26.

Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.

Clin Ther. 2020 Feb;42(2):322-337.e2. doi: 10.1016/j.clinthera.2019.12.003. Epub 2019 Dec 24.

RELATIONSHIP OF ERYTHROCYTE SURVIVAL AND RETICULOCYTE LEVELS TO SPLENECTOMY AND NEED FOR TRANSFUSION IN THALASSEMIA MAJOR.

Ann N Y Acad Sci. 1964 Oct 7;119:686-93. doi: 10.1111/j.1749-6632.1965.tb54069.x.

Effect of iron overload on impaired fertility in male patients with transfusion-dependent beta-thalassemia.

Pediatr Res. 2018 Mar;83(3):655-661. doi: 10.1038/pr.2017.296. Epub 2017 Dec 13.

Challenges of blood transfusions in β-thalassemia.

Blood Rev. 2019 Sep;37:100588. doi: 10.1016/j.blre.2019.100588. Epub 2019 Jul 6.

引用本文的文献

Long-term efficacy and safety of mitapivat in non-transfusion-dependent α- or β-thalassaemia: An open-label phase 2 study.

Br J Haematol. 2025 Jun;206(6):1764-1773. doi: 10.1111/bjh.20058. Epub 2025 May 20.

Non-Transfusion-Dependent Thalassemia: An Image Gallery Worth a Thousand Words.

Am J Hematol. 2025 Apr;100(4):687-694. doi: 10.1002/ajh.27621. Epub 2025 Jan 30.

Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study.

Haematologica. 2025 May 1;110(5):1211-1216. doi: 10.3324/haematol.2024.286886. Epub 2025 Jan 23.

Convolutional neural networks for automatic MR classification of myocardial iron overload in thalassemia major patients.

Eur Radiol. 2025 Mar;35(3):1522-1532. doi: 10.1007/s00330-024-11245-x. Epub 2024 Dec 10.

Luspatercept: a treatment for ineffective erythropoiesis in thalassemia.

Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):419-425. doi: 10.1182/hematology.2024000567.

Causes of Death and Mortality Trends in Individuals with Thalassemia in the United States, 1999-2020.

J Blood Med. 2024 Aug 5;15:331-339. doi: 10.2147/JBM.S470177. eCollection 2024.

Survival and causes of death in patients with alpha and beta-thalassemia in Northern Thailand.

Ann Med. 2024 Dec;56(1):2338246. doi: 10.1080/07853890.2024.2338246. Epub 2024 Apr 11.

How I treat non-transfusion-dependent β-thalassemia.

Blood. 2023 Sep 14;142(11):949-960. doi: 10.1182/blood.2023020683.

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.

Drug Des Devel Ther. 2023 May 25;17:1583-1591. doi: 10.2147/DDDT.S368584. eCollection 2023.

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia.

BMJ Open. 2023 Mar 22;13(3):e066683. doi: 10.1136/bmjopen-2022-066683.

本文引用的文献

Variations in hemoglobin level and morbidity burden in non-transfusion-dependent β-thalassemia.

Ann Hematol. 2021 Jul;100(7):1903-1905. doi: 10.1007/s00277-021-04456-5. Epub 2021 Feb 11.

Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years.

Am J Hematol. 2021 Mar 1;96(3):E57-E59. doi: 10.1002/ajh.26055. Epub 2020 Dec 9.

Longitudinal follow-up of patients with thalassaemia intermedia who started transfusion therapy in adulthood: a cohort study.

Br J Haematol. 2020 Oct;191(1):107-114. doi: 10.1111/bjh.16753. Epub 2020 May 19.

Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review.

Cancer. 2017 Mar 1;123(5):751-758. doi: 10.1002/cncr.30462. Epub 2016 Dec 1.

The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major-intermedia dichotomy?

Br J Haematol. 2017 Jan;176(1):124-130. doi: 10.1111/bjh.14381. Epub 2016 Oct 17.

β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies.

Haematologica. 2015 Apr;100(4):418-30. doi: 10.3324/haematol.2014.114827.

Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.

Am J Hematol. 2015 Jul;90(7):634-8. doi: 10.1002/ajh.24024. Epub 2015 May 3.

Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study.

Haematologica. 2014 Nov;99(11):e218-21. doi: 10.3324/haematol.2013.097220. Epub 2014 Jul 4.

Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry.

Br J Haematol. 2014 Oct;167(1):121-6. doi: 10.1111/bjh.13009. Epub 2014 Jul 3.

Non-transfusion-dependent thalassemias.

Haematologica. 2013 Jun;98(6):833-44. doi: 10.3324/haematol.2012.066845.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia.

作者信息

机构信息

Thalassemia Center, Burjeel Medical City, Abu Dhabi, UAE

Campus of Haematology Franco and Piera Cutino, AOOR Villa Sofia-V. Cervello, Palermo.

出版信息

Haematologica. 2021 Sep 1;106(9):2489-2492. doi: 10.3324/haematol.2021.278684.

DOI:10.3324/haematol.2021.278684

PMID:33882642

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8409024/

Abstract

摘要

相似文献

Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia.

Haematologica. 2021 Sep 1;106(9):2489-2492. doi: 10.3324/haematol.2021.278684.

Morbidities and mortality in transfusion-dependent Beta-thalassemia patients (single-center experience).

Pediatr Hematol Oncol. 2013 Mar;30(2):93-103. doi: 10.3109/08880018.2012.752054. Epub 2013 Jan 9.

Red cell alloimmunization in transfusion-dependent and transfusion-independent beta thalassemia: A review from the Eastern Mediterranean Region (EMRO).

Transfus Apher Sci. 2019 Dec;58(6):102678. doi: 10.1016/j.transci.2019.102678. Epub 2019 Nov 7.

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.

Haematologica. 2019 Mar;104(3):477-484. doi: 10.3324/haematol.2018.198887. Epub 2018 Oct 18.

Disease severity scoring system for non-transfusion-dependent thalassemia.

Eur J Intern Med. 2016 May;30:e11. doi: 10.1016/j.ejim.2015.12.008. Epub 2016 Jan 4.

Molecular basis of transfusion dependent beta-thalassemia major patients in Sabah.

J Hum Genet. 2014 Mar;59(3):119-23. doi: 10.1038/jhg.2013.131. Epub 2013 Dec 26.

Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.

Clin Ther. 2020 Feb;42(2):322-337.e2. doi: 10.1016/j.clinthera.2019.12.003. Epub 2019 Dec 24.

RELATIONSHIP OF ERYTHROCYTE SURVIVAL AND RETICULOCYTE LEVELS TO SPLENECTOMY AND NEED FOR TRANSFUSION IN THALASSEMIA MAJOR.

Ann N Y Acad Sci. 1964 Oct 7;119:686-93. doi: 10.1111/j.1749-6632.1965.tb54069.x.

Effect of iron overload on impaired fertility in male patients with transfusion-dependent beta-thalassemia.

Pediatr Res. 2018 Mar;83(3):655-661. doi: 10.1038/pr.2017.296. Epub 2017 Dec 13.

Challenges of blood transfusions in β-thalassemia.

Blood Rev. 2019 Sep;37:100588. doi: 10.1016/j.blre.2019.100588. Epub 2019 Jul 6.

引用本文的文献

Long-term efficacy and safety of mitapivat in non-transfusion-dependent α- or β-thalassaemia: An open-label phase 2 study.

Br J Haematol. 2025 Jun;206(6):1764-1773. doi: 10.1111/bjh.20058. Epub 2025 May 20.

Non-Transfusion-Dependent Thalassemia: An Image Gallery Worth a Thousand Words.

Am J Hematol. 2025 Apr;100(4):687-694. doi: 10.1002/ajh.27621. Epub 2025 Jan 30.

Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study.

Haematologica. 2025 May 1;110(5):1211-1216. doi: 10.3324/haematol.2024.286886. Epub 2025 Jan 23.

Convolutional neural networks for automatic MR classification of myocardial iron overload in thalassemia major patients.

Eur Radiol. 2025 Mar;35(3):1522-1532. doi: 10.1007/s00330-024-11245-x. Epub 2024 Dec 10.

Luspatercept: a treatment for ineffective erythropoiesis in thalassemia.

Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):419-425. doi: 10.1182/hematology.2024000567.

Causes of Death and Mortality Trends in Individuals with Thalassemia in the United States, 1999-2020.

J Blood Med. 2024 Aug 5;15:331-339. doi: 10.2147/JBM.S470177. eCollection 2024.

Survival and causes of death in patients with alpha and beta-thalassemia in Northern Thailand.

Ann Med. 2024 Dec;56(1):2338246. doi: 10.1080/07853890.2024.2338246. Epub 2024 Apr 11.

How I treat non-transfusion-dependent β-thalassemia.

Blood. 2023 Sep 14;142(11):949-960. doi: 10.1182/blood.2023020683.

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.

Drug Des Devel Ther. 2023 May 25;17:1583-1591. doi: 10.2147/DDDT.S368584. eCollection 2023.

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia.

BMJ Open. 2023 Mar 22;13(3):e066683. doi: 10.1136/bmjopen-2022-066683.

本文引用的文献

Variations in hemoglobin level and morbidity burden in non-transfusion-dependent β-thalassemia.

Ann Hematol. 2021 Jul;100(7):1903-1905. doi: 10.1007/s00277-021-04456-5. Epub 2021 Feb 11.

Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years.

Am J Hematol. 2021 Mar 1;96(3):E57-E59. doi: 10.1002/ajh.26055. Epub 2020 Dec 9.

Longitudinal follow-up of patients with thalassaemia intermedia who started transfusion therapy in adulthood: a cohort study.

Br J Haematol. 2020 Oct;191(1):107-114. doi: 10.1111/bjh.16753. Epub 2020 May 19.

Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review.

Cancer. 2017 Mar 1;123(5):751-758. doi: 10.1002/cncr.30462. Epub 2016 Dec 1.

The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major-intermedia dichotomy?

Br J Haematol. 2017 Jan;176(1):124-130. doi: 10.1111/bjh.14381. Epub 2016 Oct 17.

β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies.

Haematologica. 2015 Apr;100(4):418-30. doi: 10.3324/haematol.2014.114827.

Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.

Am J Hematol. 2015 Jul;90(7):634-8. doi: 10.1002/ajh.24024. Epub 2015 May 3.

Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study.

Haematologica. 2014 Nov;99(11):e218-21. doi: 10.3324/haematol.2013.097220. Epub 2014 Jul 4.

Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry.

Br J Haematol. 2014 Oct;167(1):121-6. doi: 10.1111/bjh.13009. Epub 2014 Jul 3.

Non-transfusion-dependent thalassemias.

Haematologica. 2013 Jun;98(6):833-44. doi: 10.3324/haematol.2012.066845.

Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献